Hansa Biopharma to host Q1 2026 interim results conference call
Lund, Sweden, 8 April, 2026. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), will publish its interim report for January – March 2026 on 23 April, 2026. Interested parties may join the Company’s quarterly conference call on the same date at 14:00 CEST / 8:00 AM EDT. The event will be hosted by Renée Aguiar-Lucander, CEO, Evan Ballantyne, CFO, Richard Philipson, CMO, and Maria Törnsén, COO and President U.S. During the call, management will review the Company’s interim financial results and provide a business and pipeline update.
